Patent Armory v. Healthplex: Five Call Routing Patents Dismissed With Prejudice in 56 Days
Patent Armory, Inc. asserted five patents spanning intelligent call routing, telephony control, and auction-based entity matching against dental benefits provider Healthplex, Inc. in the Southern District of New York. The case closed with prejudice in just 56 days — suggesting a negotiated resolution or strategic capitulation before any substantive briefing.
Five-Patent Call Routing Assertion Ends in 56-Day Prejudicial Dismissal
Patent Armory, Inc. filed this infringement action against Healthplex, Inc. on 18 October 2024 in the Southern District of New York before Judge John P. Cronan. The complaint asserted five U.S. patents — US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1 — covering intelligent communication routing, auction-based entity matching, and telephony control systems with intelligent call routing. Healthplex is a dental benefits organisation whose member-facing and provider communication infrastructure appears to have been the target of the assertion.
The case closed on 13 December 2024, just 56 days after filing, when Judge Cronan granted a request to dismiss the matter with prejudice. The dismissal is recorded under ‘Voluntary dismissal,’ suggesting Patent Armory initiated or consented to the termination. A with-prejudice dismissal extinguishes Patent Armory’s right to bring the same claims against Healthplex again — a materially stronger outcome for the defendant than a without-prejudice exit. No defendant law firm or agent appears on the public record, which is consistent with early-stage resolution before full appearance.
The 56-day lifespan is notably short even by the standards of non-practicing entity actions, which often resolve pre-discovery but typically after several months of procedural activity. The absence of any recorded defendant representation and the rapid closure suggest either a licence agreement was reached swiftly or Healthplex mounted an early challenge — such as a motion to dismiss on eligibility grounds — that prompted Patent Armory to withdraw. The public record does not disclose settlement terms, licence fees, or the specific trigger for dismissal.
Filing to Voluntary dismissal in 56 days
56 days — well below the median district court patent case duration of 2–3 years
Dismissed with prejudice: what the 56-day closure means for both parties
With-prejudice dismissal bars all future re-filing on these claims
A dismissal with prejudice under Rule 41 is a final adjudication on the merits for preclusion purposes. Patent Armory cannot re-assert any of the five patents against Healthplex for the same accused products. This is distinct from a without-prejudice exit, which would preserve the plaintiff’s option to refile. The court’s grant was voluntary in origin, meaning Patent Armory consented — but the prejudice clause operates as a permanent bar.
Permanent claim barPatent Armory surrenders all claims against Healthplex permanently
By agreeing to a with-prejudice dismissal, Patent Armory accepted that it cannot re-engage Healthplex on these five patents. Whether this reflects a licensing deal reached off-docket or a strategic retreat under litigation pressure is not disclosed in public filings. The absence of any defendant counsel on record suggests the resolution occurred before Healthplex formally engaged litigation representation — a signal of very early settlement or demand withdrawal.
Claims permanently extinguishedHealthplex exits without prejudice to its operations or future defences
Healthplex secured a permanent bar on these specific claims without any public adverse finding. If no licence was granted, the company can continue operating its communication infrastructure without further exposure from Patent Armory on these patents. If a licence was granted off-docket, the with-prejudice dismissal confirms the dispute is fully resolved. Either way, Healthplex avoided costly Markman proceedings and trial.
Full exposure eliminatedNPE call routing assertions remain a credible risk for healthcare service platforms
Patent Armory’s portfolio — covering intelligent routing, telephony control, and auction-based matching — is applicable across any organisation running automated member or patient communication systems. Healthcare benefits providers with IVR, call-centre routing, or provider-matching platforms should monitor this portfolio. The rapid closure here does not signal patent weakness; it signals either a quick licence or an effective early defence strategy that others can replicate.
Healthcare comms IP riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Patent Armory, Inc. | Company | Patent licensing entity — holder of US9456086B1 and four further call routing patentsSearch in Eureka ↗ |
| Defendant | Healthplex, Inc. | Company | Healthplex, Inc. — dental benefits and managed care organisationSearch in Eureka ↗ |
| Plaintiff counsel | Isaac Rabicoff | Attorney | Counsel for Patent Armory, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Rabicoff Law LLC | Law Firm | Representing Patent Armory, Inc.Search in Eureka ↗ |
| Presiding judge | Judge John P. Cronan | Judge | New York Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order — ‘The request to dismiss this matter with prejudice is hereby GRANTED’ — is procedurally terse but legally conclusive. The with-prejudice qualifier converts a voluntary exit into a permanent bar: Patent Armory cannot re-litigate these five patents against Healthplex. The order does not address patent validity, claim construction, or infringement merits, meaning the patents remain enforceable against third parties. The voluntary character of the dismissal suggests mutual agreement or unilateral withdrawal rather than a court-ordered termination on the merits.
US9456086B1 — Intelligent communication routing and telephony control patents
The five asserted patents span two decades of routing technology evolution. US7023979B1 and US7269253B1, with application dates in the early 2000s, cover foundational telephony control and intelligent call routing architectures. US9456086B1 (application no. US12/719827) and US10237420B1 (application no. US15/856729) represent later continuation-family grants extending into the 2010s. US10491748B1 covers auction-based entity matching — a methodology applicable to provider-to-member or agent-to-caller assignment in healthcare and insurance communications platforms.
This portfolio’s strategic breadth — spanning IVR systems, skills-based routing, and auction-matching — gives it applicability across healthcare, insurance, financial services, and any enterprise running multi-channel inbound communication infrastructure. Patent Armory’s decision to assert all five simultaneously against a single dental benefits provider suggests a bundled licensing strategy designed to maximise settlement pressure. The with-prejudice dismissal here does not affect the portfolio’s enforceability against any other defendant, and organisations with similar communication architectures should treat these patents as live enforcement risk.
Should your organisation run an FTO against Patent Armory’s call routing portfolio?
Any organisation operating automated member communication systems, IVR-based call routing, provider-matching platforms, or auction-style call distribution infrastructure should assess exposure to this five-patent portfolio. The patents are particularly relevant to healthcare payers, dental and medical benefits administrators, insurance contact centres, and telecoms intermediaries. The Healthplex action signals that Patent Armory is actively monetising this portfolio in the healthcare vertical — making FTO analysis a near-term priority for IP and product teams in adjacent sectors.
PatSnap Eureka’s FTO Search Agent can map your product’s communication architecture against the claim sets of US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1 — identifying potential overlap, design-around opportunities, and prior art relevant to validity challenges. For in-house teams evaluating whether to licence or contest, Eureka’s citation graph and family tracker also surface continuation risk: whether Patent Armory holds pending applications that could extend this portfolio’s reach.
Run a freedom-to-operate analysis on US9456086B1 to assess your product’s exposure
Run FTO in Eureka →Similar NPE call routing patent cases in federal district courts
Explore comparable intelligent call routing and telephony patent assertions filed by NPEs in S.D.N.Y. and other federal districts, including outcome patterns and resolution timelines.
What this case signals for the healthcare communications IP landscape
A 56-day NPE action dismissed with prejudice raises as many questions as it answers for IP teams in the healthcare sector.
With-prejudice exits protect defendants more than they appear to signal plaintiff weakness
A with-prejudice dismissal is often misread as a plaintiff conceding patent invalidity. In practice, it may reflect a confidential licence. Healthcare IP teams should treat this as a resolved threat — not a defeated one — and monitor whether Patent Armory re-asserts the same portfolio against comparable defendants.
Absence of defendant counsel on record suggests pre-litigation resolution playbook
No defendant law firm appears on the S.D.N.Y. docket. This pattern — NPE files, defendant resolves before formal appearance — is consistent with a demand-letter-to-licence pipeline. In-house teams receiving demand letters on call routing patents should benchmark this case as a potential cost-of-response data point.
Patent v Healthplex — key questions answered
Patent Armory asserted five U.S. patents: US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1. These patents cover intelligent communication routing systems, telephony control with intelligent call routing, and auction-based entity matching methods — all relevant to automated member and provider communication infrastructure.
The public record records the termination as a voluntary dismissal with prejudice granted by Judge Cronan on 13 December 2024. The specific trigger — whether a licence agreement, a settlement payment, or a strategic withdrawal under threat of an early § 101 motion — is not disclosed in public filings. The 56-day duration and absence of defendant counsel on record suggest very early-stage resolution.
No. A dismissal with prejudice following a voluntary motion does not constitute a ruling on patent validity or infringement. The five patents remain in force and enforceable against third parties. The dismissal only bars Patent Armory from re-asserting these specific claims against Healthplex for the accused products.
No defendant law firm or agent appears on the public S.D.N.Y. docket for this case. This is consistent with resolution occurring before Healthplex formally entered an appearance — a pattern common in NPE demand-letter-to-licence scenarios where the defendant resolves the dispute directly or through informal counsel engagement not reflected in court filings.
Yes, the portfolio warrants attention. Patent Armory’s five-patent stack spans foundational through mid-generation call routing and entity matching technology, with broad applicability to healthcare payers, benefits administrators, and insurance contact centres. The Healthplex action confirms active enforcement in the healthcare vertical. A freedom-to-operate review against the asserted claims is advisable for organisations operating comparable communication systems.
PatSnap Eureka searches patents and litigation data to answer instantly.